Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1121 daily bars · split adjusted
Current price $17.47
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Sep 15, 26 |
Daily · Wilder smoothing
| Needham |
| maintain |
| Hold |
| Hold |
| Aug 28, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Aug 3, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Jul 30, 26 | UBS | maintain | Buy | Buy |
| Jul 8, 26 | Citigroup | maintain | Buy | Buy |
| Jul 6, 26 | Evercore ISI Group | maintain | In Line | In Line |
| Apr 30, 26 | Citigroup | maintain | Buy | Buy |
| Apr 30, 26 | Evercore ISI Group | maintain | In Line | In Line |
| Apr 6, 26 | Evercore ISI Group | maintain | In Line | In Line |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 58.24 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 93.10 | Oscillator | Sell |
| Williams %R (14) | -1.48 | Oscillator | Sell |
| MACD (12, 26, 9) | 0.01 (Hist 0.10) | Oscillator | Strong Buy |
| Average Directional Index (14) | 14.52 (+DI 21.1 / -DI 19.0) | Trend | Neutral |
| EMA 20 | 16.94 | MA | Strong Buy |
| SMA 20 | 16.90 | MA | Strong Buy |
| EMA 50 | 16.94 | MA | Strong Buy |
| SMA 50 | 17.14 | MA | Buy |
| SMA 200 | 16.63 | MA | Strong Buy |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Aug 12, 26 | Trebbi Barbara | director | A-Award | 11,776 | — |
| Aug 5, 26 | Trebbi Barbara | director: | 0 | — | |
| Aug 12, 26 | Paul Laurence E | director | A-Award | 11,776 | — |
| Aug 5, 26 | Paul Laurence E | director: | 0 | — | |
| Aug 12, 26 | Chersi Robert J | director | A-Award | 11,776 | — |
| Aug 5, 26 | Chersi Robert J | director: | 0 | — | |
| Aug 5, 26 | Appio Thomas | director | 0 | — | |
| Aug 10, 26 | Munsch Frederick | officer: SVP, Controller and CAO | S-Sale | 52,900 @ $16.78 | $887.7K |
TTM vs. 5-year historical average (annual ratios)
| Metric | BLCO | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -36.5x | 68.0x · sector 20.7x | Discount |
| Forward P/E (FY26E) | 22.0x | EPS est. 0.79 | Discount |
| Price / Book | 1.0x | 0.9x | In line |
| Price / Sales | 1.2x | 1.5x | Discount |
| EV / EBITDA | 14.8x | 16.4x | In line |
| Return on equity | -2.7% | — | Weak |
| Gross margin | 57.2% | 59.4% | In line |
| Debt / Equity | 0.80 | 0.53 | Moderate |
| Piotroski / Altman Z | 4/9 | Z 0.95 | Distress |
Discounted cash flow model
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 8-K | Oct 13, 2026 | 2026-10-13 06:09:48 | View |
| 4 | Aug 14, 2026 | 2026-08-14 17:47:44 | View |
| 3 | Aug 14, 2026 | 2026-08-14 17:45:12 | View |
| 4 | Aug 14, 2026 | 2026-08-14 17:34:42 | View |
| 3 | Aug 14, 2026 | 2026-08-14 17:33:19 | View |
| 4 | Aug 14, 2026 | 2026-08-14 17:25:45 | View |
| 3 | Aug 14, 2026 | 2026-08-14 17:22:43 | View |
| 3 | Aug 14, 2026 | 2026-08-14 17:09:46 | View |
| 4 | Aug 12, 2026 | 2026-08-12 19:06:22 | View |
| 8-K/A | Aug 12, 2026 | 2026-08-12 07:01:08 | View |
Proxy statement (DEF 14A) disclosures
Stock news · updated daily
Bausch + Lomb Corporation (NYSE: BLCO - Get Free Report)'s stock price fell 5.8% during mid-day trading on Monday. The company traded as low as $16.13 and last traded at $16.2990. Approximately 154,963 shares traded hands during trading, a decline of 63% from the average daily volume of 414,952 shares. The stock had previously closed at
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company, and its parent company, Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced that Bausch + Lomb Board of Directors Chairman Thomas J. Appio has been appointed interim chief executive officer, effective immediately. Appio will continue to serve as CEO of Bausch Health while assuming leadership of Bausch + Lomb. Appio was appointed chairman of the Bausch + Lomb Board of Dir.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Jul 29, 2026 | 0.15 | 0.16 | Beat 3.6% | $1.39B |
| Apr 29, 2026 | 0.06 | 0.08 | Beat 33.3% | $1.24B |
| Feb 18, 2026 | 0.35 | 0.32 | Miss -8.6% | $1.41B |
| Oct 29, 2025 | 0.16 | 0.18 | Beat 12.5% | $1.28B |
| Jul 30, 2025 | 0.06 | 0.07 | Beat 16.7% | $1.28B |
| Apr 30, 2025 | 0.03 | -0.07 | Miss -333.3% | $1.13B |